What is Mimedx Group Inc's earnings per share (EPS)?

Mimedx Group Inc (MDXG) reported diluted earnings per share of $0.32 for fiscal year 2025. This represents a 14.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Mimedx Group Inc Financials

MDXG

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Mimedx Group Inc (MDXG) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 72/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Mimedx Group Inc has an operating margin of 15.3%, meaning the company retains $15 of operating profit per $100 of revenue. This results in a moderate score of 56/100, indicating healthy but not exceptional operating efficiency. This is down from 16.9% the prior year.

Growth

Mimedx Group Inc's revenue surged 20.0% year-over-year to $418.6M, reflecting rapid business expansion. This strong growth earns a score of 67/100.

Leverage

100

Mimedx Group Inc carries a low D/E ratio of 0.06, meaning only $0.06 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 4.32, Mimedx Group Inc holds $4.32 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 85/100.

Returns

Mimedx Group Inc's ROE of 18.9% shows moderate profitability relative to equity, earning a score of 53/100. This is down from 22.0% the prior year.

Altman Z-Score Safe

6.47

Mimedx Group Inc scores 6.47, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($582.4M) relative to total liabilities ($86.1M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Neutral

5/9

Mimedx Group Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed

1.52x

For every $1 of reported earnings, Mimedx Group Inc generates $1.52 in operating cash flow ($74.0M OCF vs $48.6M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

35.8x

Mimedx Group Inc earns $35.8 in operating income for every $1 of interest expense ($63.9M vs $1.8M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$418.6M

YoY+20.0%

5Y CAGR+11.0%

10Y CAGR+8.4%

Mimedx Group Inc generated $418.6M in revenue in fiscal year 2025. This represents an increase of 20.0% from the prior year.

EBITDA

$78.8M

YoY+21.4%

10Y CAGR+11.3%

Mimedx Group Inc's EBITDA was $78.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 21.4% from the prior year.

Net Income

$48.6M

YoY+14.5%

10Y CAGR+5.1%

Mimedx Group Inc reported $48.6M in net income in fiscal year 2025. This represents an increase of 14.5% from the prior year.

EPS (Diluted)

$0.32

YoY+14.3%

10Y CAGR+2.1%

Mimedx Group Inc earned $0.32 per diluted share (EPS) in fiscal year 2025. This represents an increase of 14.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$166.1M

YoY+59.1%

5Y CAGR+11.6%

10Y CAGR+20.2%

Mimedx Group Inc held $166.1M in cash against $16.5M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

148M

YoY+0.8%

5Y CAGR+5.9%

10Y CAGR+3.2%

Mimedx Group Inc had 148M shares outstanding in fiscal year 2025. This represents an increase of 0.8% from the prior year.

Margins & Returns

Gross Margin

82.6%

YoY-0.2pp

5Y CAGR-1.6pp

10Y CAGR-6.7pp

Mimedx Group Inc's gross margin was 82.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.2 percentage points from the prior year.

Operating Margin

15.3%

YoY-1.6pp

5Y CAGR+33.6pp

10Y CAGR+2.3pp

Mimedx Group Inc's operating margin was 15.3% in fiscal year 2025, reflecting core business profitability. This is down 1.6 percentage points from the prior year.

Net Margin

11.6%

YoY-0.6pp

5Y CAGR+31.4pp

10Y CAGR-4.1pp

Mimedx Group Inc's net profit margin was 11.6% in fiscal year 2025, showing the share of revenue converted to profit. This is down 0.6 percentage points from the prior year.

Return on Equity

18.9%

YoY-3.0pp

10Y CAGR-65.9pp

Mimedx Group Inc's ROE was 18.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 3.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$15.1M

YoY+22.3%

5Y CAGR+5.2%

10Y CAGR+6.0%

Mimedx Group Inc invested $15.1M in research and development in fiscal year 2025. This represents an increase of 22.3% from the prior year.

Share Buybacks

Mimedx Group Inc spent $0 on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

N/A

MDXG Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$418.6M+20.0%	$348.9M+8.5%	$321.5M+20.0%	$267.8M+10.7%	$242.0M-2.5%	$248.2M
Cost of Revenue	$73.0M+21.5%	$60.1M+10.0%	$54.6M+13.1%	$48.3M+21.9%	$39.6M+0.8%	$39.3M
Gross Profit	$345.6M+19.7%	$288.8M+8.2%	$266.8M+21.6%	$219.5M+8.5%	$202.4M-3.1%	$208.9M
R&D Expenses	$15.1M+22.3%	$12.3M-2.6%	$12.7M-0.3%	$12.7M+27.9%	$9.9M-15.2%	$11.7M
SG&A Expenses	$266.2M+18.3%	$225.1M+6.6%	$211.1M+1.2%	$208.7M+7.1%	$194.8M+7.6%	$181.0M
Operating Income	$63.9M+8.5%	$58.9M+58.6%	$37.1M+352.0%	-$14.7M-108.9%	-$7.1M+84.5%	-$45.4M
Interest Expense	$1.8M-54.7%	$3.9M-40.1%	$6.6M+30.2%	$5.0M+201.4%	-$5.0M+37.3%	-$7.9M
Income Tax	$17.7M+15.6%	$15.3M+141.6%	-$36.8M-17967.0%	$206K-16.6%	$247K+102.0%	-$12.3M
Net Income	$48.6M+14.5%	$42.4M-27.2%	$58.2M+292.8%	-$30.2M-193.6%	-$10.3M+79.1%	-$49.3M
EPS (Diluted)	$0.32+14.3%	$0.28-24.3%	$0.37+212.1%	$-0.33-120.0%	$-0.15+80.5%	$-0.77

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$118.1M+3.8%	$113.7M+15.3%	$98.6M+11.8%	$88.2M-5.1%	$92.9M+10.5%	$84.1M-3.6%	$87.2M+2.9%	$84.7M
Cost of Revenue	$19.1M+1.8%	$18.7M+0.2%	$18.7M+12.8%	$16.6M-2.1%	$16.9M+10.4%	$15.3M+3.1%	$14.9M+14.4%	$13.0M
Gross Profit	$99.0M+4.2%	$95.0M+18.9%	$79.9M+11.6%	$71.6M-5.7%	$76.0M+10.6%	$68.7M-5.0%	$72.4M+0.9%	$71.7M
R&D Expenses	$4.8M+28.6%	$3.7M+12.1%	$3.3M-0.8%	$3.3M-6.8%	$3.6M+22.3%	$2.9M-3.1%	$3.0M+6.0%	$2.8M
SG&A Expenses	$73.1M+5.9%	$69.0M+7.6%	$64.2M+7.0%	$60.0M-1.8%	$61.0M+14.1%	$53.5M-3.4%	$55.4M+0.5%	$55.1M
Operating Income	$21.1M-5.0%	$22.2M+79.4%	$12.4M+49.9%	$8.3M-25.4%	$11.1M-1.0%	$11.2M-52.4%	$23.4M+77.7%	$13.2M
Interest Expense	$405K-4.7%	$425K-10.5%	$475K-0.6%	$478K-8.3%	$521K0.0%	$521K-0.2%	$522K-78.0%	$2.4M
Income Tax	$6.6M+8.3%	$6.1M+80.0%	$3.4M+113.3%	$1.6M-58.3%	$3.8M+7.7%	$3.5M-36.7%	$5.6M+138.3%	$2.3M
Net Income	$15.2M-9.3%	$16.7M+74.1%	$9.6M+37.0%	$7.0M-5.6%	$7.4M-8.1%	$8.1M-54.1%	$17.6M+90.3%	$9.3M
EPS (Diluted)	N/A	$0.11+83.3%	$0.06+20.0%	$0.05	N/A	$0.05-58.3%	$0.12+100.0%	$0.06

MDXG Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$342.7M+29.8%	$263.9M+10.4%	$239.0M+39.4%	$171.4M-8.8%	$187.9M-7.0%	$202.0M
Current Assets	$277.5M+44.6%	$191.9M+16.8%	$164.3M+22.4%	$134.2M-9.6%	$148.5M-7.5%	$160.6M
Cash & Equivalents	$166.1M+59.1%	$104.4M+27.3%	$82.0M+24.3%	$66.0M-24.3%	$87.1M-9.1%	$95.8M
Inventory	$25.3M+6.4%	$23.8M+13.3%	$21.0M+59.5%	$13.2M+15.8%	$11.4M+9.9%	$10.4M
Accounts Receivable	$75.7M+35.6%	$55.8M+3.6%	$53.9M+25.0%	$43.1M+6.8%	$40.4M+13.9%	$35.4M
Goodwill	$19.4M0.0%	$19.4M0.0%	$19.4M0.0%	$19.4M0.0%	$19.4M-2.7%	$20.0M
Total Liabilities	$86.1M+21.6%	$70.8M-26.5%	$96.3M-49.1%	$189.4M+0.8%	$187.8M-7.1%	$202.2M
Current Liabilities	$64.3M+40.9%	$45.6M-0.9%	$46.0M+5.6%	$43.6M+2.8%	$42.4M-28.4%	$59.2M
Long-Term Debt	$16.5M-7.6%	$17.8M-62.9%	$48.1M-1.0%	$48.6M+1.0%	$48.1M+0.9%	$47.7M
Total Equity	$256.5M+32.9%	$193.1M+35.3%	$142.7M+893.4%	-$18.0M-22036.6%	$82K+154.7%	-$150K
Retained Earnings	-$42.7M+53.2%	-$91.3M+31.7%	-$133.7M+30.3%	-$191.9M-18.7%	-$161.7M-6.8%	-$151.4M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$342.7M+7.4%	$319.0M+9.6%	$291.1M+7.7%	$270.4M+2.5%	$263.9M+8.2%	$243.9M+6.0%	$230.2M+3.8%	$221.7M
Current Assets	$277.5M+9.2%	$254.1M+15.0%	$220.9M+10.4%	$200.1M+4.3%	$191.9M+11.5%	$172.1M+11.8%	$154.0M+10.9%	$138.9M
Cash & Equivalents	$166.1M+16.9%	$142.1M+19.5%	$118.9M+11.7%	$106.4M+1.9%	$104.4M+17.6%	$88.8M+28.6%	$69.0M+42.4%	$48.5M
Inventory	$25.3M-4.4%	$26.5M+6.5%	$24.9M+3.4%	$24.1M+1.1%	$23.8M-1.8%	$24.2M-3.2%	$25.1M+2.5%	$24.5M
Accounts Receivable	$75.7M-3.2%	$78.2M+12.9%	$69.2M+11.1%	$62.3M+11.6%	$55.8M+3.3%	$54.0M+2.3%	$52.8M-7.4%	$57.0M
Goodwill	$19.4M0.0%	$19.4M0.0%	$19.4M0.0%	$19.4M0.0%	$19.4M0.0%	$19.4M0.0%	$19.4M0.0%	$19.4M
Total Liabilities	$86.1M+7.6%	$80.0M+7.5%	$74.5M+10.1%	$67.6M-4.5%	$70.8M+12.6%	$62.9M+1.2%	$62.1M-5.8%	$66.0M
Current Liabilities	$64.3M+11.4%	$57.7M+14.7%	$50.3M+18.0%	$42.6M-6.5%	$45.6M+8.7%	$41.9M+4.8%	$40.0M-5.2%	$42.2M
Long-Term Debt	$16.5M-2.2%	$16.8M-2.2%	$17.2M-1.8%	$17.5M-1.7%	$17.8M-1.0%	$18.0M-1.3%	$18.2M-1.1%	$18.5M
Total Equity	$256.5M+7.4%	$238.9M+10.3%	$216.6M+6.8%	$202.8M+5.0%	$193.1M+6.7%	$181.0M+7.7%	$168.0M+7.9%	$155.7M
Retained Earnings	-$42.7M+26.2%	-$57.9M+22.4%	-$74.6M+11.4%	-$84.2M+7.7%	-$91.3M+7.5%	-$98.7M+7.6%	-$106.8M+14.2%	-$124.4M

MDXG Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$74.0M+11.8%	$66.2M+147.2%	$26.8M+249.6%	-$17.9M-802.8%	-$2.0M+93.5%	-$30.3M
Capital Expenditures	N/A	N/A	$2.0M+31.2%	$1.5M-53.0%	$3.2M	N/A
Free Cash Flow	N/A	N/A	$24.8M+227.7%	-$19.4M-273.2%	-$5.2M	N/A
Investing Cash Flow	-$6.9M+28.1%	-$9.6M-344.7%	-$2.2M+19.0%	-$2.7M+21.6%	-$3.4M+25.5%	-$4.6M
Financing Cash Flow	-$5.4M+84.2%	-$34.2M-299.1%	-$8.6M-1377.6%	-$580K+82.7%	-$3.4M-105.4%	$61.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0	$0-100.0%	$9.5M	$0	$0-100.0%	$900K

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$25.0M-14.9%	$29.3M+103.4%	$14.4M+172.1%	$5.3M-71.8%	$18.8M-4.3%	$19.6M-10.0%	$21.8M+264.9%	$6.0M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$335K+93.6%	-$5.3M-492.8%	-$887K-118.5%	-$406K+85.3%	-$2.8M-2548.7%	$113K+112.5%	-$905K+85.0%	-$6.0M
Financing Cash Flow	-$583K+32.0%	-$857K+21.7%	-$1.1M+62.0%	-$2.9M-619.5%	-$400K-1581.5%	$27K+107.5%	-$359K+98.9%	-$33.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

MDXG Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	82.6%-0.2pp	82.8%-0.2pp	83.0%+1.0pp	82.0%-1.7pp	83.6%-0.5pp	84.2%
Operating Margin	15.3%-1.6pp	16.9%+5.3pp	11.6%+17.1pp	-5.5%-2.6pp	-2.9%+15.4pp	-18.3%
Net Margin	11.6%-0.6pp	12.2%-6.0pp	18.1%+29.4pp	-11.3%-7.0pp	-4.3%+15.6pp	-19.9%
Return on Equity	18.9%-3.0pp	22.0%-18.8pp	40.8%	N/A	-12542.7%	N/A
Return on Assets	14.2%-1.9pp	16.1%-8.3pp	24.4%+42.0pp	-17.6%-12.1pp	-5.5%+18.9pp	-24.4%
Current Ratio	4.32+0.1	4.21+0.6	3.57+0.5	3.08-0.4	3.51+0.8	2.71
Debt-to-Equity	0.06-0.0	0.09-0.2	0.34+3.0	-2.70-589.6	586.91+904.9	-317.98
FCF Margin	N/A	N/A	7.7%+15.0pp	-7.2%-5.1pp	-2.1%	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	83.9%+0.3pp	83.5%+2.5pp	81.0%-0.2pp	81.2%-0.6pp	81.8%+0.0pp	81.8%-1.2pp	83.0%-1.7pp	84.7%
Operating Margin	17.8%-1.7pp	19.5%+7.0pp	12.6%+3.2pp	9.3%-2.5pp	11.9%-1.4pp	13.3%-13.6pp	26.9%+11.3pp	15.6%
Net Margin	12.9%-1.9pp	14.7%+5.0pp	9.8%+1.8pp	8.0%-0.1pp	8.0%-1.6pp	9.6%-10.6pp	20.2%+9.3pp	10.9%
Return on Equity	5.9%-1.1pp	7.0%+2.6pp	4.4%+1.0pp	3.5%-0.4pp	3.9%-0.6pp	4.5%-6.0pp	10.5%+4.5pp	5.9%
Return on Assets	4.4%-0.8pp	5.3%+1.9pp	3.3%+0.7pp	2.6%-0.2pp	2.8%-0.5pp	3.3%-4.3pp	7.7%+3.5pp	4.2%
Current Ratio	4.32-0.1	4.41+0.0	4.39-0.3	4.70+0.5	4.21+0.1	4.10+0.3	3.85+0.6	3.29
Debt-to-Equity	0.060.0	0.070.0	0.080.0	0.090.0	0.090.0	0.100.0	0.110.0	0.12
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Maravai Lifesciences Holdings, Inc. MRVI

$431.8M

180 Life Sciences Corp ATNF

$1.1B

Xeris Biopharma Holdings XERS

$1.0B

Intellia Therape NTLA

$1.6B

Maze Therapeutics MAZE

$1.4B

Frequently Asked Questions

What is Mimedx Group Inc's annual revenue?

Mimedx Group Inc (MDXG) reported $418.6M in total revenue for fiscal year 2025. This represents a 20.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Mimedx Group Inc's revenue growing?

Mimedx Group Inc (MDXG) revenue grew by 20% year-over-year, from $348.9M to $418.6M in fiscal year 2025.

Is Mimedx Group Inc profitable?

Yes, Mimedx Group Inc (MDXG) reported a net income of $48.6M in fiscal year 2025, with a net profit margin of 11.6%.

What is Mimedx Group Inc's EBITDA?

Mimedx Group Inc (MDXG) had EBITDA of $78.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Mimedx Group Inc have?

As of fiscal year 2025, Mimedx Group Inc (MDXG) had $166.1M in cash and equivalents against $16.5M in long-term debt.

What is Mimedx Group Inc's gross margin?

Mimedx Group Inc (MDXG) had a gross margin of 82.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Mimedx Group Inc's operating margin?

Mimedx Group Inc (MDXG) had an operating margin of 15.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Mimedx Group Inc's net profit margin?

Mimedx Group Inc (MDXG) had a net profit margin of 11.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Mimedx Group Inc's return on equity (ROE)?

Mimedx Group Inc (MDXG) has a return on equity of 18.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Mimedx Group Inc's operating cash flow?

Mimedx Group Inc (MDXG) generated $74.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Mimedx Group Inc's total assets?

Mimedx Group Inc (MDXG) had $342.7M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Mimedx Group Inc spend on research and development?

Mimedx Group Inc (MDXG) invested $15.1M in research and development during fiscal year 2025.

How many shares does Mimedx Group Inc have outstanding?

Mimedx Group Inc (MDXG) had 148M shares outstanding as of fiscal year 2025.

What is Mimedx Group Inc's current ratio?

Mimedx Group Inc (MDXG) had a current ratio of 4.32 as of fiscal year 2025, which is generally considered healthy.

What is Mimedx Group Inc's debt-to-equity ratio?

Mimedx Group Inc (MDXG) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Mimedx Group Inc's return on assets (ROA)?

Mimedx Group Inc (MDXG) had a return on assets of 14.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Mimedx Group Inc's Altman Z-Score?

Mimedx Group Inc (MDXG) has an Altman Z-Score of 6.47, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Mimedx Group Inc's Piotroski F-Score?

Mimedx Group Inc (MDXG) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Mimedx Group Inc's earnings high quality?

Mimedx Group Inc (MDXG) has an earnings quality ratio of 1.52x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Mimedx Group Inc cover its interest payments?

Mimedx Group Inc (MDXG) has an interest coverage ratio of 35.8x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Mimedx Group Inc?

Mimedx Group Inc (MDXG) scores 72 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.